QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Developing and Maintaining RMPs for Biological Medicinal Products

Test your understanding of the concepts covered by How to Develop and Maintain Risk Management Plans for Biological Medicinal Products.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which information is particularly important when characterising exposure to a biological product after authorisation?

Only the total number of prescriptions, without product or route details. Exposure stratified where relevant by indication, route, presentation, switching and product identity. Only the number of patients enrolled in pivotal trials. Only spontaneous reports with no denominator or exposure context.

Question 2 of 10 Which statement correctly distinguishes Part IV from Part III?

Part IV concerns post-authorisation efficacy studies when efficacy uncertainty has benefit–risk implications; Part III concerns additional safety evidence. Part IV contains all routine pharmacovigilance activities; Part III contains only risk-minimisation measures. Part IV is limited to device complaints; Part III is limited to clinical trials. There is no substantive distinction between the two parts.

Question 3 of 10 What should an additional risk-minimisation measure specify most clearly?

That the product is complex and therefore deserves educational material. The preventable pathway, target audience, behavioural objective and method for assessing effectiveness. Only the number of copies distributed to healthcare professionals. That the measure will eliminate the risk completely.

Question 4 of 10 What should QPPV oversight principally ensure for a biological medicine’s RMP?

That the QPPV personally authors every table in the document. That classifications are evidence-based, quality and manufacturing information can inform safety assessment, activities are feasible, measures are measurable and agreed changes are controlled. That every reported adverse event becomes an important identified risk. That the RMP remains unchanged after authorisation unless an authority directly requests a revision.

Question 5 of 10 What is the appropriate interpretation of no opportunistic infections observed in a clinical programme with limited exposure?

The risk is absent for the product. The risk is excluded because clinical trials are more reliable than all other evidence. The observation provides some information but may not reliably exclude a very rare event. The event should automatically be classified as an identified risk.

Question 6 of 10 A component defect causes incomplete doses in one injector lot and is associated with disease flares. Which update is most appropriate?

Automatically reclassify the event as an active-substance lack-of-efficacy risk for all presentations. Investigate the lot- and device-specific concern, reconcile complaints and cases, assess its RMP importance, and update relevant measures and indicators if justified. Delete the issue from the RMP because the defect is confined to one lot. Address the issue only through the public summary and make no changes to supporting systems.

Question 7 of 10 When does an under-represented population constitute missing information for an RMP?

Whenever the population was excluded from any clinical trial. Only when the population is larger than the studied population. When the gap is clinically relevant to authorised or expected use and limits safety prediction. Only when regulators have already identified an adverse reaction in that population.

Question 8 of 10 Which statement best distinguishes an EU RMP from a PBRER?

The RMP prospectively defines current uncertainties, additional evidence, controls and reassessment points, whereas the PBRER evaluates accumulated evidence over a defined period. The RMP is limited to adverse reactions already included in the product information, whereas the PBRER covers only unlabelled risks. The RMP evaluates manufacturing compliance, whereas the PBRER evaluates clinical efficacy only. The RMP is prepared only after authorisation, whereas the PBRER is required with the initial marketing-authorisation application.

Question 9 of 10 Which statement most accurately differentiates a US REMS from an EU RMP?

A REMS is the US name for the mandatory EU RMP format. A REMS is an FDA-required programme for selected serious risks, whereas an EU RMP is a broader lifecycle risk-management document submitted with EU initial applications. A REMS covers only routine pharmacovigilance, whereas an EU RMP covers only additional measures. The two frameworks are interchangeable if their risk concerns have the same names.

Question 10 of 10 Which finding most strongly supports classification of a concern as an important identified risk?

A theoretical mechanism without human evidence. A single unverified report with no plausible temporal relationship. Adequate evidence of an association, together with potential impact on the benefit–risk balance or public health. An adverse reaction listed in the product information, regardless of seriousness or relevance.

Knowledge Assessment: Developing and Maintaining RMPs for Biological Medicinal Products

Cookie Settings